[1] Beltrani VS. Atopic dermatitis: An update.J Allergy Clin Immunol, 1999,104(Suppl): S85-S86.
[2] Valenta R, Seiberler S, Natter S, et al. Autoallergy: a pathogenetic factor in atopic dermatitis? J Allergy Clin Immunol, 2000,105:432-437.
[3] Wollenberg A, Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy, 2000,55:205-213.
[4] Yu G,Bjorksten B.Polyunsaturated fatty acids in school children in relation to allergy and serum IgE levels.Pediatr Allergy Immunol,1998, 9:133-138.
[5] Leung DY. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol, 1999, 104(Suppl):S99-S108.
[6] Parnia S, Frew AJ. Chemokines and atopic dermatitis. J Allergy Clin Immunol, 2000,105:892-894.
[7] Koblenzer CS. Itching and the atopic dermatitis. J Allergy Clin Immunol, 1999,104(Suppl): S109-S113.
[8] Beltrani VS. The Clinical spectrum of atopic dermatitis. J Allergy Clin Immunol, 1999,104(Suppl):S87-S98.
[9] Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol, 1999,104(Suppl):S114-S122.
[10] Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol,2000,105:860-876.
[11] Leung DY. Therapeutic perspectives in atopic dermatitis. Allergy, 1999,54(Suppl 58):39-42.
[12] Ruzicka T,Assmann T,Homey B. Tacro limus: The drug for the turn of the millennium? Arch Dermatol, 1999, 135:574-580.
[13] Van Leent EJ, Graber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol, 1998,134:805-809. |
